Araştırma Makalesi

Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome

Cilt: 20 Sayı: 3 1 Ekim 2023
PDF İndir
TR EN

Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome

Öz

Aim: The myeloperoxidase/paraoxonase1(MPO/PON1) ratio is known to reflect the dysfunctional HDL(d-HDL) which is a measure of oxidative stress. This study aimed to evaluate the MPO/PON1 ratio in polycystic ovary syndrome(PCOS). Materials and Method: This prospective study included a total of 123 patients. The study group including the women with the diagnosis of PCOS (n=63) was compared to the control group including the healthy women (n=60). Sociodemographic characteristics, and clinical features of the groups were recorded. Serum HDL level, MPO, and PON1 activities were evaluated. Results: The PCOS patients were observed to have increased MPO and decreased PON1 activities (p<0.0001 and p=0.007, respectively). The d-HDL and was found to be significantly higher in PCOS patients compared to the healthy controls (0.56 (0.24) vs. 0.50 (0.12), p<0.0001). There were also significant associations between the oxidative parameters and PCOS related findings (p<0.05). Conclusion: Besides the increased MPO/PON1 ratio which defined as d-HDL, the increased MPO and decreased PON1 activities also supported the increased oxidative status in PCOS patients. Our results may be considered to draw attention to oxidative stress and dyslipidemia in PCOS patients, even in the early periods of the women life.

Anahtar Kelimeler

Kaynakça

  1. 1. Escobar-Morreale HF. Polycystic ovary syndrome: de- finition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-84. 2. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analy- sis. Hum Reprod Update. 2011;17(4):495-500. 3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993-1007. 4. Perovic Blagojevic IM, Vekic JZ, Macut DP, Ignjato- vic SD, Miljkovic-Trailovic MM, Zeljkovic AR, et al. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2022;128(4):604-12. 5. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fo- narow GC. High-density lipoprotein function recent advances. J Am Coll Cardiol. 2005;46(10):1792-8.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Kadın Hastalıkları ve Doğum

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

1 Ekim 2023

Gönderilme Tarihi

12 Haziran 2023

Kabul Tarihi

6 Temmuz 2023

Yayımlandığı Sayı

Yıl 2023 Cilt: 20 Sayı: 3

Kaynak Göster

APA
Erol Koç, E. M., Yaman, S., Ceyhan, M., Neselioglu, S., Erel, Ö., & Doğanay, M. (2023). Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, 20(3), 1804-1809. https://doi.org/10.38136/jgon.1313215
AMA
1.Erol Koç EM, Yaman S, Ceyhan M, Neselioglu S, Erel Ö, Doğanay M. Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. JGON. 2023;20(3):1804-1809. doi:10.38136/jgon.1313215
Chicago
Erol Koç, Esin Merve, Selen Yaman, Meryem Ceyhan, Salim Neselioglu, Özcan Erel, ve Melike Doğanay. 2023. “Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome”. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi 20 (3): 1804-9. https://doi.org/10.38136/jgon.1313215.
EndNote
Erol Koç EM, Yaman S, Ceyhan M, Neselioglu S, Erel Ö, Doğanay M (01 Ekim 2023) Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi 20 3 1804–1809.
IEEE
[1]E. M. Erol Koç, S. Yaman, M. Ceyhan, S. Neselioglu, Ö. Erel, ve M. Doğanay, “Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome”, JGON, c. 20, sy 3, ss. 1804–1809, Eki. 2023, doi: 10.38136/jgon.1313215.
ISNAD
Erol Koç, Esin Merve - Yaman, Selen - Ceyhan, Meryem - Neselioglu, Salim - Erel, Özcan - Doğanay, Melike. “Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome”. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi 20/3 (01 Ekim 2023): 1804-1809. https://doi.org/10.38136/jgon.1313215.
JAMA
1.Erol Koç EM, Yaman S, Ceyhan M, Neselioglu S, Erel Ö, Doğanay M. Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. JGON. 2023;20:1804–1809.
MLA
Erol Koç, Esin Merve, vd. “Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome”. Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi, c. 20, sy 3, Ekim 2023, ss. 1804-9, doi:10.38136/jgon.1313215.
Vancouver
1.Esin Merve Erol Koç, Selen Yaman, Meryem Ceyhan, Salim Neselioglu, Özcan Erel, Melike Doğanay. Evaluation of the myeloperoxidase/paraoxonase1 ratio as the determinant of dysfunctional HDL in polycystic ovary syndrome. JGON. 01 Ekim 2023;20(3):1804-9. doi:10.38136/jgon.1313215